Correlation Between Neurosense Therapeutics and Cingulate Warrants

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Neurosense Therapeutics and Cingulate Warrants at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurosense Therapeutics and Cingulate Warrants into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neurosense Therapeutics and Cingulate Warrants, you can compare the effects of market volatilities on Neurosense Therapeutics and Cingulate Warrants and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurosense Therapeutics with a short position of Cingulate Warrants. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurosense Therapeutics and Cingulate Warrants.

Diversification Opportunities for Neurosense Therapeutics and Cingulate Warrants

0.13
  Correlation Coefficient

Average diversification

The 3 months correlation between Neurosense and Cingulate is 0.13. Overlapping area represents the amount of risk that can be diversified away by holding Neurosense Therapeutics and Cingulate Warrants in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cingulate Warrants and Neurosense Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurosense Therapeutics are associated (or correlated) with Cingulate Warrants. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cingulate Warrants has no effect on the direction of Neurosense Therapeutics i.e., Neurosense Therapeutics and Cingulate Warrants go up and down completely randomly.

Pair Corralation between Neurosense Therapeutics and Cingulate Warrants

Given the investment horizon of 90 days Neurosense Therapeutics is expected to under-perform the Cingulate Warrants. But the stock apears to be less risky and, when comparing its historical volatility, Neurosense Therapeutics is 5.17 times less risky than Cingulate Warrants. The stock trades about -0.3 of its potential returns per unit of risk. The Cingulate Warrants is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  4.30  in Cingulate Warrants on August 31, 2024 and sell it today you would lose (1.15) from holding Cingulate Warrants or give up 26.74% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy95.65%
ValuesDaily Returns

Neurosense Therapeutics  vs.  Cingulate Warrants

 Performance 
       Timeline  
Neurosense Therapeutics 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Neurosense Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy basic indicators, Neurosense Therapeutics is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.
Cingulate Warrants 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Cingulate Warrants has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable technical and fundamental indicators, Cingulate Warrants is not utilizing all of its potentials. The current stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Neurosense Therapeutics and Cingulate Warrants Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Neurosense Therapeutics and Cingulate Warrants

The main advantage of trading using opposite Neurosense Therapeutics and Cingulate Warrants positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurosense Therapeutics position performs unexpectedly, Cingulate Warrants can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cingulate Warrants will offset losses from the drop in Cingulate Warrants' long position.
The idea behind Neurosense Therapeutics and Cingulate Warrants pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Fundamental Analysis
View fundamental data based on most recent published financial statements
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation